Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

NCT03370276 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT03370276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03370276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 1/2
Overall status
Completed
Start date
December 20, 2017
Completion date
December 23, 2023
Enrollment
95 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck carcinoma, head and neck squamous cell carcinoma, squamous cell cancer, squamous cell carcinoma of the hypopharynx, squamous cell carcinoma of the larynx, squamous cell carcinoma of the oral cavity, squamous cell carcinoma of the oropharynx, squamous cell carcinoma of the paranasal sinus